30-day average of 8 articles Β· scale β100 to +100
Across 8 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Becton, Dickinson and Company news is Somewhat Bullish (+44)
on a scale from β100 to +100.
That is up 13 points from the previous 30 days (+31).
π Revenue hit $5.27B, beating estimates by $160M.
π° EPS reached $4.15, topping consensus by $0.08.
Bullish +72
Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. Sells ...
AI-generated analysis
Key insights
π Becton, Dickinson and Company reported quarterly revenue of $5.27 billion, beating analyst estimates of $5.11 billion by $160 million.
π° The company posted earnings per share of $4.15, topping the consensus estimate of $4.07 by $0.08.
π BDX authorized a new share repurchase plan allowing the buyback of up to 10 million shares or 3.6% of outstanding equity.
π΅ The company declared a quarterly dividend of $1.06 per share, an increase from the previous quarter's $1.05 payout.
π CEO Thomas Polen Jr. sold 2,993 shares for $628,530 under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 2.65%.
π¦ BlackRock Inc. increased its position in BDX by approximately $3.7 billion during the second quarter.
π State Street Corp boosted its holdings by 8.5%, adding over 1.1 million shares to its portfolio.
π Zacks Research upgraded BDX from a 'hold' rating to a 'strong-buy' rating in late October.
π― The consensus analyst target price for BDX is $195.47, with Jefferies Financial Group setting a high target of $242.
π Bullish signals
πRevenue grew 5.4% year-over-year to $5.27 billion, exceeding analyst consensus estimates of $5.11 billion.
π°Earnings per share reached $4.15, beating the expected $4.07 by $0.08, demonstrating strong operational execution.
πThe company authorized a new share repurchase program for up to 10 million shares, signaling management confidence in the stock's valuation.
π΅Becton, Dickinson and Company increased its quarterly dividend to $1.06 per share from the previous $1.05.
π¦Major institutional investors including BlackRock, State Street, and First Eagle significantly increased their holdings in the second quarter.
πZacks Research upgraded the stock to a 'strong-buy' rating following the strong quarterly earnings beat.
π Risk factors
πThe CEO sold 2,993 shares worth $628,530, representing a 2.65% reduction in his personal stake, though executed under a pre-arranged trading plan.
πBarclays initiated coverage with an 'underweight' rating and set a price objective of $165, which is below the current market price.
Article
Becton, Dickinson and Company (NYSE:BDX) reported strong quarterly financial results for the period ending in late October, with revenue reaching $5.27 billion, a 5.4% year-over-year increase that beat analyst consensus estimates of $5.11 billion. The company posted earnings per share of $4.15, surpassing the expected $4.07, while maintaining a net margin of 4.52% and a return on equity of 14.79%. This performance highlights the medical instruments supplier's ability to grow revenue and profitability in its core healthcare markets.
Following the earnings release, the company announced a new share repurchase plan authorizing the buyback of up to 10 million shares, representing approximately 3.6% of its outstanding equity. Additionally, BDX declared a quarterly dividend of $1.06 per share, payable on December 31st to shareholders of record by December 10th. This marks an increase from the previous quarterly dividend of $1.05, reflecting a commitment to returning capital to investors despite a payout ratio exceeding 100%.
Institutional investor sentiment remains robust, with major funds like BlackRock, State Street, and First Eagle increasing their stakes in the second quarter. Analyst consensus is moderately bullish, with an average target price of $195.47 and recent upgrades from Zacks Research to a 'strong-buy' rating. While CEO Thomas Polen Jr. sold shares under a pre-arranged plan, the broader market data suggests confidence in BDX's long-term trajectory.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Becton, Dickinson and Company (NYSE:BDX) reported strong quarterly financial results for the period ending in late October, with revenue reaching $5.27 billion, a 5.4% year-over-year increase that beat analyst consensus estimates of $5.11 billion. The company posted earnings per share of $4.15, surpassing the expected $4.07, while maintaining a net margin of 4.52% and a return on equity of 14.79%. This performance highlights the medical instruments supplier's ability to grow revenue and profitability in its core healthcare markets.
Following the earnings release, the company announced a new share repurchase plan authorizing the buyback of up to 10 million shares, representing approximately 3.6% of its outstanding equity. Additionally, BDX declared a quarterly dividend of $1.06 per share, payable on December 31st to shareholders of record by December 10th. This marks an increase from the previous quarterly dividend of $1.05, reflecting a commitment to returning capital to investors despite a payout ratio exceeding 100%.
Institutional investor sentiment remains robust, with major funds like BlackRock, State Street, and First Eagle increasing their stakes in the second quarter. Analyst consensus is moderately bullish, with an average target price of $195.47 and recent upgrades from Zacks Research to a 'strong-buy' rating. While CEO Thomas Polen Jr. sold shares under a pre-arranged plan, the broader market data suggests confidence in BDX's long-term trajectory.
π Revenue hit $5.27B, beating estimates by $160M.
π° EPS reached $4.15, topping consensus by $0.08.
π Authorized buyback of 10M shares or 3.6% equity.
π΅ Dividend increased to $1.06 per share.
π Upgraded to 'strong-buy' with $242 high target.
π Becton, Dickinson and Company reported quarterly revenue of $5.27 billion, beating analyst estimates of $5.11 billion by $160 million.
π° The company posted earnings per share of $4.15, topping the consensus estimate of $4.07 by $0.08.
π BDX authorized a new share repurchase plan allowing the buyback of up to 10 million shares or 3.6% of outstanding equity.
π΅ The company declared a quarterly dividend of $1.06 per share, an increase from the previous quarter's $1.05 payout.
π CEO Thomas Polen Jr. sold 2,993 shares for $628,530 under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 2.65%.
π¦ BlackRock Inc. increased its position in BDX by approximately $3.7 billion during the second quarter.
π State Street Corp boosted its holdings by 8.5%, adding over 1.1 million shares to its portfolio.
π Zacks Research upgraded BDX from a 'hold' rating to a 'strong-buy' rating in late October.
π― The consensus analyst target price for BDX is $195.47, with Jefferies Financial Group setting a high target of $242.
Bullish Signals
Revenue grew 5.4% YoY to $5.27B, beating estimates.
EPS hit $4.15, beating expectations by $0.08.
Authorized repurchase of up to 10 million shares.
Quarterly dividend increased to $1.06 per share.
Upgraded to 'strong-buy' after earnings beat.
Risk Factors
CEO sold 2,993 shares worth $628,530.
Barclays initiated underweight with $165 target.
Bullish Signals
Revenue grew 5.4% year-over-year to $5.27 billion, exceeding analyst consensus estimates of $5.11 billion.
Earnings per share reached $4.15, beating the expected $4.07 by $0.08, demonstrating strong operational execution.
The company authorized a new share repurchase program for up to 10 million shares, signaling management confidence in the stock's valuation.
Becton, Dickinson and Company increased its quarterly dividend to $1.06 per share from the previous $1.05.
Major institutional investors including BlackRock, State Street, and First Eagle significantly increased their holdings in the second quarter.
Zacks Research upgraded the stock to a 'strong-buy' rating following the strong quarterly earnings beat.
Risk Factors
The CEO sold 2,993 shares worth $628,530, representing a 2.65% reduction in his personal stake, though executed under a pre-arranged trading plan.
Barclays initiated coverage with an 'underweight' rating and set a price objective of $165, which is below the current market price.
Becton Dickinson (BDX) reported a Q4 fiscal 2026 earnings beat with sales of US$5,274m and net income of US$696m. The company raised its quarterly dividend to US$1.06 and authorized repurchases of up to 10 million shares, signaling a strategic focus on capital returns and recurring medtech platforms.
Management provided guidance for low single-digit GAAP revenue growth in fiscal 2027, maintaining the existing investment narrative despite near-term headwinds like the Alaris replacement cycle and weaker China demand. Full-year sales reached US$19.5b, with reported net income at US$1.1b including large one-off items.
Analysts project revenues of US$21.4b and earnings of US$3.3b by 2029, though some estimates suggest potential downside risks to fair value. Key operational supports include the BD Excellence productivity program and product launches such as Liverty TIPS, while ongoing legal issues like Bard PowerPort litigation remain a risk factor.
The article highlights BDX's reliance on steady consumables sales rather than big swings, noting that debt is not well covered by operating cash flow. Investors are advised to weigh the company's resilient compounder status against potential regulatory and product quality risks that could pressure margins.
π BDX Q4 2026 sales hit $5,274m and net income $696m, beating expectations.
π° Dividend raised to $1.06 with authorization for up to 10 million share repurchases.
β οΈ China demand weakness and Alaris replacement cycle pose near-term headwinds.
π‘οΈ BD Excellence productivity program execution is critical for future growth support.
βοΈ Bard PowerPort litigation and debt coverage risks threaten margins and cash flow.
π Becton Dickinson reported Q4 fiscal 2026 sales of US$5,274m and net income of US$696m, beating market expectations.
π° The company raised its quarterly dividend to US$1.06 and authorized repurchases of up to 10 million shares.
π Management guided for low single-digit GAAP revenue growth in fiscal 2027, maintaining the current outlook.
β οΈ Known headwinds include the Alaris replacement cycle and weaker demand in China affecting near-term performance.
π BDX is focusing on recurring medtech platforms and cash generation through its core consumables business.
βοΈ Analyst forecasts project revenues of US$21.4b by 2029, though some estimates indicate potential downside to fair value.
π‘οΈ Operational execution on the BD Excellence productivity program is critical to supporting future growth.
βοΈ The ongoing Bard PowerPort litigation and product quality issues remain significant risks to margins and cash flow.
πΈ Debt levels are flagged as not well covered by operating cash flow, requiring disciplined capital spending.
π Full-year fiscal 2026 sales reached US$19.5b with reported net income of US$1.1b including one-off items.
Bullish Signals
Q4 earnings beat with sales of US$5,274m and net income of US$696m.
Raised quarterly dividend to US$1.06 and authorized 10 million share repurchases.
Becton Dickinson and Company (BDX) reported fourth-quarter earnings of $4.15 per share, surpassing the Zacks Consensus Estimate of $4.06. This result represents a 2.22% positive surprise compared to analyst expectations, continuing a streak where the company has beaten EPS estimates for four consecutive quarters. Revenue for the quarter ended September 2026 reached $5.27 billion, exceeding consensus estimates by 2.96%, although this figure is lower than the year-ago period of $5.89 billion.
The stock has gained approximately 7.8% year-to-date, trailing the S&P 500's 12.3% gain. Despite the underperformance relative to the broader market so far this year, BDX maintains a Zacks Rank #2 (Buy) rating based on favorable earnings estimate revisions ahead of the report. The company operates within the Medical - Dental Supplies industry, which currently ranks in the top 30% among all tracked industries.
Looking forward, the consensus EPS estimate for the coming quarter is set at $2.69 with projected revenues of $4.77 billion. For the current fiscal year, analysts expect earnings of $13.24 on revenues totaling $19.91 billion. The sustainability of BDX's stock price movement will largely depend on management's commentary during the upcoming earnings call and subsequent trends in earnings estimate revisions.
π Q4 EPS beat estimates by 2.22% at $4.15 per share.
π° Revenue hit $5.27 billion, up 2.96% from consensus.
π BDX topped EPS estimates for four consecutive quarters.
π Shares rose 7.8% YTD with a Zacks Rank #2 Buy.
π Q1 projected at $2.69 EPS on $4.77 billion revenue.
π Becton Dickinson reported Q4 earnings of $4.15 per share, beating the consensus estimate of $4.06 by 2.22%.
π° Quarterly revenue reached $5.27 billion, surpassing analyst expectations by 2.96% despite being lower than the prior year's $5.89 billion.
π The company has topped consensus EPS estimates for four consecutive quarters over the last twelve months.
π BDX shares have risen approximately 7.8% year-to-date, though they have underperformed the S&P 500's 12.3% gain.
π The stock holds a Zacks Rank #2 (Buy) rating due to favorable earnings estimate revisions prior to the report release.
π Analysts project Q1 consensus EPS of $2.69 on revenues of $4.77 billion for the upcoming quarter.
π₯ Becton Dickinson operates in the Medical - Dental Supplies industry, which is currently ranked in the top 30% of all industries.
Bullish Signals
Beat Q4 EPS by $0.09 for fourth consecutive quarter.
Revenue hit $5.27B, exceeding forecasts by 2.96%.
Holds Zacks Rank #2 Buy rating.
Risk Factors
Revenue dropped from $5.89B to $5.27B.
Stock underperformed S&P 500 by 4.5% YTD.
Bullish Signals
The company beat Q4 earnings estimates by $0.09 per share, marking the fourth consecutive quarter of surpassing consensus EPS expectations.
Revenue of $5.27 billion exceeded analyst forecasts by 2.96%, demonstrating consistent ability to meet or exceed market predictions.
The stock maintains a Zacks Rank #2 (Buy) rating, indicating a high probability of outperforming the market based on favorable earnings estimate trends.
Risk Factors
Quarterly revenue of $5.27 billion was significantly lower than the year-ago figure of $5.89 billion, indicating a potential decline in top-line growth.
The stock has underperformed the broader S&P 500 index by approximately 4.5 percentage points since the beginning of the year.
Becton Dickinson and Company (BDX) shares surged approximately 4.13% during regular trading on November 4, 2026, reaching an intraday high of $208.57. This significant move added roughly $2.3 billion to the company's market capitalization, which stood at approximately $56.8 billion at the time of the report. The rally was characterized by sustained buying pressure through the middle of the session rather than a fade, suggesting underlying demand durability for this large-cap medtech name.
The stock closed the day at $193.76, establishing a fresh 52-week high that sits 1.51% above the previous peak recorded on August 21. This performance marks a notable departure from the company's recent trajectory, as BDX had spent most of the spring trading in the $140s range. The magnitude of this single-session swing is considered unusual for a medtech company of this size, warranting close observation to determine if the gains can hold into the market close and carry forward into the next session.
Investors are now focused on whether the stock can maintain its momentum near the $209.08 level in subsequent trading. The ability to consolidate near these highs will be critical in determining if this represents a sustainable trend reversal or a temporary spike. Analysts and traders are watching closely to see if the buying built through the session indicates a shift in sentiment that could sustain the price above its prior peak.
π BDX shares surged 4.13% to a fresh 52-week high of $193.76.
π° Rally added $2.3 billion to market cap, now valued at $56.8 billion.
π Sustained buying pressure built through the session indicating durable demand.
π― Investors watch if stock holds gains near $209.08 level forward.
π Becton Dickinson shares surged 4.13% during regular trading on November 4, 2026, reaching an intraday high of $208.57.
π° The rally added approximately $2.3 billion to the company's market capitalization, which was valued at roughly $56.8 billion.
π BDX closed the session at $193.76, establishing a fresh 52-week high that is 1.51% above the prior peak set on August 21.
π The stock had spent most of the spring trading in the $140s range before this significant upward move.
π Sustained buying pressure built through the middle of the session rather than fading, suggesting durable demand.
π― Investors are watching whether the stock can hold gains near the $209.08 level into the close and forward.
Becton Dickinson and Company (BDX) is preparing to report quarterly earnings for the period ended September 2026, with results expected on November 5. Analysts anticipate a year-over-year earnings per share increase of 2.5% to $4.06, despite a projected revenue decline of 13% to $5.12 billion.
The consensus EPS estimate has been revised upward by 0.19% over the last 30 days, driven by analysts revising their Most Accurate Estimates higher than the standard consensus. This revision results in a positive Zacks Earnings ESP of +0.21%, indicating that the company is likely to beat earnings expectations.
BDX currently holds a Zacks Rank of #2 (Buy), which historically increases the predictive power of a positive Earnings ESP reading. The company has a strong track record, having beaten consensus EPS estimates in four of its last five reported quarters, with the most recent surprise being +2.87%.
π Becton Dickinson reports Q3 2026 earnings on November 5.
π° Analysts expect $4.06 EPS, a 2.5% year-over-year increase.
π Revenue forecast is $5.12 billion, down 13% from last year.
π Consensus EPS estimate revised up 0.19% in the last 30 days.
π Zacks Rank #2 (Buy) and positive ESP model suggest earnings beat.
π Becton Dickinson is scheduled to release quarterly earnings for the quarter ended September 2026 on November 5.
π° Analysts expect EPS of $4.06 per share, representing a 2.5% year-over-year increase.
π Revenue is forecasted at $5.12 billion, down 13% from the same quarter last year.
π The consensus EPS estimate has been revised up by 0.19% in the last 30 days.
π― The Zacks Earnings ESP model shows a positive reading of +0.21%, suggesting an earnings beat.
π BDX holds a Zacks Rank of #2 (Buy), reinforcing the likelihood of a positive surprise.
π The company has beaten EPS estimates in four out of its last five quarters.
Becton Dickinson (BDX) has gained investor attention following a new U.S. manufacturing agreement and positive execution updates ahead of its fourth quarter fiscal 2026 earnings report. The stock has demonstrated strong momentum, with a 90-day share price return of 25.16% and a one-year total shareholder return of 39.61%, suggesting building rather than fading interest.
The company is executing a strategic shift toward a focused medtech portfolio where over 90% of revenue comes from businesses growing in the mid-to-high single digits. Key platforms, including biologic drug delivery, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration, are growing at double-digit rates with gross margins exceeding the corporate average, supporting a richer margin mix.
Valuation perspectives on BDX remain mixed. While one narrative suggests the stock is 2% overvalued relative to a fair value of $195.67, a Discounted Cash Flow (DCF) model values future cash flows at $234.50 per share against the current trading price of $198.91. This discrepancy indicates a potential built-in discount rather than a premium, though pressure in China and potential regulatory or product quality issues pose risks to the valuation.
π BDX secured new U.S. manufacturing agreement ahead of Q4 fiscal 2026 earnings.
π Stock delivered 25.16% return in 90 days and 39.61% total shareholder return last year.
π Over 90% revenue now comes from mid-to-high single-digit growth businesses in focused portfolio.
π Key platforms growing double digits with higher gross margins including biologic drug delivery.
β οΈ China market pressure and product quality risks could challenge current valuation premium.
π Becton Dickinson secured a new U.S. manufacturing agreement and reported positive execution updates ahead of its Q4 fiscal 2026 earnings.
π The stock has delivered a 25.16% return over the last 90 days and a 39.61% total shareholder return over the past year.
π The company is pivoting to a focused medtech portfolio where over 90% of revenue comes from mid-to-high single-digit growth businesses.
π Key platforms like biologic drug delivery, Advanced Patient Monitoring, PureWick, and tissue regeneration are growing at double digits with higher gross margins.
βοΈ Valuation analysis shows mixed signals, with one model pricing the stock as 2% overvalued at $195.67 fair value versus a current price of $198.91.
π An alternative SWS DCF model values BDX shares at $234.50 based on projected future cash flows, suggesting a potential discount to the market price.
β οΈ The stock faces headwinds from ongoing pressure in the China market which could challenge its current valuation premium.
π‘οΈ Potential risks include fresh product quality issues or regulatory setbacks that could impact the company's growth trajectory.
Bullish Signals
Secured new U.S. manufacturing agreement ahead of Q4 fiscal 2026 earnings.
Risk Factors
China market pressure threatens valuation premium.
Stock trades above $195.67 fair value.
Bullish Signals
Becton Dickinson secured a new U.S. manufacturing agreement and reported positive execution updates ahead of its upcoming Q4 fiscal 2026 earnings report.
The stock has achieved a strong 90-day share price return of 25.16% and a one-year total shareholder return of 39.61%, indicating building investor momentum.
Over 90% of the company's revenue now comes from businesses growing in the mid-to-high single digits, reflecting a successful strategic shift to a focused medtech portfolio.
Key platforms including biologic drug delivery, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration are growing at double-digit rates with gross margins exceeding the corporate average.
Risk Factors
Ongoing pressure in the China market poses a risk that could quickly challenge the company's current valuation premium.
The stock is currently trading modestly above a widely followed narrative fair value of $195.67, framing recent momentum against an already full long-term outlook.
Becton Dickinson (BDX) and Boston Scientific (BSX) are being compared as investment alternatives within the healthcare sector, with BDX showing a year-to-date gain of 32.9% against the broader market. The analysis highlights that while BDX trades at a higher earnings multiple of 55.7x compared to BSX's 18.0x, this valuation premium is driven by thin net margins of 4.0% and recent fiscal Q2 losses.
Becton Dickinson management recently raised its adjusted EPS forecast for fiscal 2026, projecting revenue growth toward the high end of its low single-digit range. However, the company anticipates a drag of 200 basis points on revenue growth in fiscal 2027 specifically due to challenges within its Alaris business unit.
In contrast to BDX's cautious outlook, Boston Scientific has lowered its fiscal 2026 revenue growth forecast to 6.0% amid a sharp slowdown in the WATCHMAN market and share losses in electrophysiology. Additionally, BSX faces potential material impacts from a cyberattack disrupting manufacturing and shipments, which complicates its third-quarter and full-year results.
Becton Dickinson and Company (BDX) shares closed at $193.76 on October 15, 2026, establishing a fresh 52-week high that marks a significant recovery from the spring trading range where the stock hovered in the $140s.
The medtech giant, valued at approximately $52.8 billion, has demonstrated persistent upward momentum over the back half of the year, attracting attention from institutional buyers who typically favor names trading near their highs.
Technical analysts are now monitoring whether the new high of $193.76 holds as a support floor on any potential pullback. A successful defense of this level would confirm that prior resistance has flipped to become support, validating the breakout for momentum investors.
π BDX closed at $193.76, setting a new 52-week high above $182.25.
π° Shares recovered from spring range between $140 and $150.
ποΈ The $52.8 billion medtech leader climbed persistently through late 2026.
π Fresh high signals buyer control and attracts institutional interest.
π Holding $193.76 support is critical to confirm breakout strength.
π Becton Dickinson closed at $193.76 on October 15, setting a new 52-week high above its previous peak of $182.25 established in August.
π° The company has recovered substantially from the spring trading range where shares spent most of the season between $140 and $150.
ποΈ As a $52.8 billion market cap medtech leader, BDX has strung together a persistent climb through the back half of 2026.
π The fresh high signals continued buyer control and attracts institutional interest from investors favoring names trading at or near their highs.
π Technical levels suggest that holding $193.76 as a support floor is critical to confirm the breakout lacks follow-through if failed.
Becton Dickinson shares closed at a fresh 52-week high of $193.76, signaling strong buyer control and substantial recovery from the spring lows.
The company has maintained persistent upward momentum through the back half of the year, attracting institutional buyers who favor names trading near their highs.
Becton, Dickinson and Company (NYSE: BDX) reported a 5.4% year-over-year revenue increase to $4.98 billion in the third quarter of fiscal 2026, driven by steady demand for its medical devices and exposure to essential healthcare spending. Adjusted diluted earnings per share rose 4.9% to $3.23, leading the company to raise its full-year adjusted EPS guidance midpoint to $12.67, representing approximately 6.5% growth compared to fiscal 2025.
The stock currently trades at a forward P/E of 13.72x and offers a dividend yield of roughly 2.4%, with an implied payout ratio around 33% based on the updated guidance. Operating cash flow from ongoing operations surged 33.3% to $2.10 billion in the first nine months of fiscal 2026, while free cash flow jumped 44.6% to $1.73 billion, providing robust support for its dividend and potential for reinvestment or debt reduction.
Despite the positive financial metrics, analysts note that revenue growth remains in low single digits even after excluding currency effects, making margin expansion critical. The company faces risks related to product litigation, restructuring costs, and integration expenses following the separation of its Biosciences and Diagnostic Solutions business in February 2026. While the valuation appears discounted relative to some peers like Medtronic and Stryker, sustainability of adjusted earnings is key to realizing long-term value.
π Q3 revenue grew 5.4% YoY to $4.98 billion.
π° Adjusted EPS rose 4.9% to $3.23.
π Full-year adjusted EPS guidance raised to $12.67.
π΅ Dividend yield stands at 2.4% with $4.20 payout.
π Operating cash flow surged 33.3% to $2.10 billion.
π Becton, Dickinson and Company reported Q3 fiscal 2026 revenue growth of 5.4% year over year, reaching $4.98 billion.
π° Adjusted diluted earnings per share increased 4.9% to $3.23 in the third quarter of fiscal 2026.
π The company raised its full-year adjusted EPS guidance midpoint to $12.67, up from $11.90 in fiscal 2025.
π΅ BDX offers a dividend yield of approximately 2.4% with an annual payout of $4.20 per share.
π Operating cash flow from ongoing operations rose 33.3% to $2.10 billion in the first nine months of fiscal 2026.
πΈ Free cash flow increased significantly by 44.6% to $1.73 billion during the same period.
π The stock trades at a forward P/E ratio of 13.72x, which is lower than peers Medtronic and Stryker.
β οΈ Revenue growth remains in low single digits when currency effects are eliminated, requiring margin expansion.
βοΈ The company faces potential headwinds from product-related litigation, restructuring, and integration costs.
π BDX separated its Biosciences and Diagnostic Solutions business in February 2026, altering its earnings profile.
Bullish Signals
Revenue grew 5.4% YoY to $4.98B in Q3 FY2026.
Adjusted diluted EPS rose 4.9% to $3.23.
Operating cash flow surged 33.3% to $2.10B.
Free cash flow increased 44.6% to $1.73B.
Trades at forward P/E of 13.72x vs peers.
Risk Factors
Revenue growth is low single digits excluding currency effects.
Risks include litigation, remediation, restructuring, and integration costs.
Adjusted earnings sustainability challenged by non-recurring charges.
Bullish Signals
Revenue grew 5.4% year over year to $4.98 billion in Q3 fiscal 2026, demonstrating steady demand for medical devices.
Adjusted diluted EPS rose 4.9% to $3.23, leading the company to raise its full-year adjusted EPS guidance midpoint to $12.67.
Operating cash flow from ongoing operations surged 33.3% to $2.10 billion in the first nine months of fiscal 2026.
Free cash flow increased 44.6% to $1.73 billion, providing strong support for its dividend and future growth initiatives.
The stock trades at a forward P/E of 13.72x, which is lower than peers Medtronic (14.93x) and Stryker (16.47x).
BDX has a long history of dividend growth, having achieved 54 years of consecutive increases as a Dividend King.
The implied payout ratio is around 33% based on fiscal 2026 adjusted EPS guidance, leaving room for reinvestment or debt reduction.
Risk Factors
Revenue growth remains in low single digits when currency effects are eliminated, necessitating margin expansion to sustain profitability.
The company faces risks from product-related litigation, remediation expenses, restructuring, and integration costs following the business separation.
Adjusted earnings must prove sustainable as GAAP profitability could be impacted by non-recurring charges and one-time costs.
Becton Dickinson (BDX) recently released positive nine-month clinical data from the AGILITY trial for its Revello Vascular Covered Stent, which successfully met its primary endpoint in treating iliac artery disease. This development adds to a busy October for the company, characterized by a new U.S. government manufacturing partnership and a leadership change within its Surgery unit.
Despite facing an active product recall that highlights ongoing execution risks across its portfolio, BDX's stock has demonstrated significant momentum, gaining 20.28% over the past 90 days. The company is executing a strategic shift toward a focused medtech portfolio where over 90% of revenue comes from businesses growing in the mid-to-high single digits, with key platforms like biologic drug delivery and Advanced Patient Monitoring growing at double-digit rates.
Following the separation of its Waters division, Becton Dickinson has adopted a shareholder-friendly capital allocation strategy, including approximately $2.3 billion in share repurchases year-to-date in fiscal 2026 and the retirement of $2.1 billion in debt while maintaining net leverage around 2.9x. Analysts currently view the stock as undervalued with a fair value estimate of $195.67 against a recent closing price of $182.75, suggesting potential upside despite risks related to persistent weakness in China and potential regulatory actions on infection prevention products.
π€ The company secured a new U.S. government manufacturing partnership during a busy October that also saw a leadership change in its Surgery unit.
π BDX shares have rallied 20.28% over the past 90 days, driven by momentum despite a year-to-date decline of 6.25%.
π Over 90% of Becton Dickinson's revenue now comes from businesses growing in the mid-to-high single digits following its strategic portfolio focus.
π° Following the Waters separation, the company returned $3.1 billion to shareholders and retired $2.1 billion in debt while keeping net leverage at 2.9x.
π Key platforms including biologic drug delivery, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration are growing at double-digit rates with higher gross margins.
β οΈ An active product recall underscores ongoing execution risks across Becton Dickinson's broader portfolio.
π¨π³ The company faces real pressure if weakness in the Chinese market persists or impacts its global operations.
βοΈ Analysts estimate a fair value of $195.67 for BDX, indicating the stock may still be undervalued despite recent gains.
π¬ Potential risks include expanded FDA actions or longer resolution times regarding infection prevention products.
Bullish Signals
Revello Vascular Stent hit primary endpoint in AGILITY trial.
Secured new U.S. government manufacturing partnership.
Shares gained 20.28% over past 90 days.
90% revenue from mid-to-high single-digit growth businesses.
Key platforms growing double-digits with higher gross margins.
Weakness in China threatens global revenue streams.
FDA actions on infection products may expand.
Bullish Signals
Becton Dickinson's Revello Vascular Covered Stent successfully hit its primary endpoint in the AGILITY trial for iliac artery disease, validating the product's efficacy.
The company secured a new U.S. government manufacturing partnership, signaling strong demand and operational capacity.
BDX shares have gained 20.28% over the past 90 days, reflecting strong investor momentum and market confidence.
More than 90% of revenue comes from businesses growing in the mid-to-high single digits, providing a stable foundation for earnings growth.
Key platforms such as biologic drug delivery, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration are growing at double-digit rates with higher gross margins than the corporate average.
Following the Waters separation, Becton Dickinson has executed significant capital returns including $2.3 billion in share repurchases year-to-date in fiscal 2026.
The company retired $2.1 billion of debt while maintaining a healthy net leverage ratio of approximately 2.9x, strengthening its balance sheet.
Risk Factors
An active product recall highlights ongoing execution risks that could impact reputation or sales across the broader portfolio.
The company faces significant pressure if weakness in the Chinese market persists, which could affect global revenue streams.
There is a risk that FDA actions regarding infection prevention products could expand or take longer to resolve than anticipated.
Becton Dickinson has committed to investing $19 billion in the United States under a new agreement with the Trump administration designed to secure protection against future tariffs. This deal marks Becton Dickinson as the first major US medical device manufacturer to reach such an accord, signaling a significant strategic shift towards domestic production capabilities.
The group plans to direct these investments toward expanding its production facilities, operations, and supply chain, with $3 billion specifically earmarked for strategic manufacturing sites. A key component of this plan involves increasing US production of essential medical consumables by approximately 5 billion units annually, which is expected to raise the share of these products sourced domestically to about 80%.
Furthermore, Becton Dickinson intends to manufacture all needles intended for the US market within the United States using domestically produced steel. In exchange for this commitment, certain products and inputs may benefit from reduced future tariffs under Section 232, though the specific financial impact remains unquantified pending final details on rates and implementation schedules.
This agreement aligns with the administration's broader strategy to use tariffs to encourage reshoring within the healthcare sector. Notably, over $1 billion of the strategic site investment will go toward Nebraska, building upon a previous January announcement of an $110 million investment in Columbus, Nebraska, aimed at expanding prefilled syringe and cannula production while creating approximately 120 jobs.
π Becton Dickinson commits to historic $19 billion US investment under Trump administration agreement.
π Company invests $3 billion in strategic manufacturing sites to bolster US production capabilities.
πΊπΈ US medical consumables output rises 5 billion units/year, reaching 80% domestic sourcing target.
π‘οΈ Deal positions Becton Dickinson as first major player protected against future tariffs.
π· Columbus expansion creates 120 jobs for prefilled syringes and cannulas with $1B+ funding.
π Becton Dickinson commits to a historic $19 billion investment in the United States under a new agreement with the Trump administration.
π The company will invest $3 billion specifically in strategic manufacturing sites to bolster its US production capabilities and supply chain.
πΊπΈ US production of essential medical consumables is expected to increase by approximately 5 billion units per year, reaching an 80% domestic sourcing target.
𧡠All needles for the US market will be manufactured domestically using steel produced within the United States.
π‘οΈ The agreement positions Becton Dickinson as the first major US medical device player to secure protection against future tariffs.
π° Over $1 billion of the strategic investment is designated for Nebraska, expanding on a prior $110 million commitment in Columbus.
π· The Columbus, Nebraska expansion will focus on prefilled syringes and cannulas while creating approximately 120 new jobs.
βοΈ Certain products and inputs may qualify for reduced future tariffs under Section 232 as part of the deal's incentives.
Bullish Signals
Secures unique $19B US investment commitment from Trump administration.
Plans 5B annual unit production increase in US facilities.
Commits to domestic needle manufacturing using US steel.
Potential tariff reductions under Section 232 could improve margins.
Nebraska expansion adds $1B+ investment and 120 jobs.
Bullish Signals
Becton Dickinson secures a unique $19 billion investment commitment in the US, becoming the first major medical device sector player to reach such an agreement with the Trump administration.
The company plans to increase US production of essential medical consumables by approximately 5 billion units annually, significantly boosting domestic sourcing to roughly 80%.
Becton Dickinson commits to manufacturing all needles for the US market domestically using domestic steel, strengthening its supply chain resilience.
The agreement includes potential benefits from reduced future tariffs under Section 232, which could improve margins on specific products and inputs once finalized.
A substantial portion of the investment ($1 billion+) is directed to Nebraska, expanding a previous $110 million Columbus facility that will create approximately 120 jobs.
Becton Dickinson and Company (BDX) shares are trading at EUR 157.63 in pre-market sessions on October 5, 2026, representing a modest gain of 0.34% against the previous close of EUR 157.10. The stock is listed on the NYSE with an ISIN of US0758871091 and is currently being quoted by Lang & Schwarz with a bid of EUR 156.05 and an ask of EUR 159.20 ahead of the Xetra open.
Significant corporate developments include the appointment of Arthur Hu as executive vice president and chief information and digital officer, effective September 30, 2026. Hu joins BD from Lenovo to succeed retiring executive Denise Russell Fleming, marking a strategic leadership transition in the company's digital operations.
Additionally, Becton Dickinson celebrated a major milestone at its Sandy, Utah manufacturing facility, which recently marked its 70th anniversary of production. The site employs over 1,000 people and is responsible for producing peripheral intravenous catheters and molded components, highlighting the company's long-standing operational footprint in medical device manufacturing.
The article provides a snapshot of BDX's current market price and highlights key internal appointments and facility anniversaries that underscore the company's ongoing strategic focus on digital transformation and established manufacturing capabilities.
π BDX stock trades at EUR 157.63, up 0.34% pre-market.
π€ Arthur Hu named CIO effective Sept 30, replacing Denise Russell Fleming.
π Sandy Utah facility celebrates 70 years with 1,000+ employees.
π» New CIO appointment signals continued digital transformation focus.
π Leadership updates and milestones released in late September 2026.
π Becton Dickinson stock is trading at EUR 157.63 in pre-market sessions, up 0.34% from the prior close of EUR 157.10.
π€ Arthur Hu has been named executive vice president and chief information and digital officer, effective September 30, succeeding retiring executive Denise Russell Fleming.
π Becton Dickinson's Sandy, Utah facility marked 70 years of manufacturing operations while employing more than 1,000 people to produce peripheral intravenous catheters.
π» The new CIO appointment signals a continued strategic focus on digital transformation and information technology leadership within the medical device sector.
π The company released updates regarding its leadership transition and operational milestones in late September 2026.
Bullish Signals
Appointed Arthur Hu as EVP and CIO from Lenovo.
Sandy, Utah facility employs 1,000+ for 70 years.
Bullish Signals
Becton Dickinson appointed Arthur Hu as executive vice president and chief information and digital officer, bringing experience from Lenovo to lead the company's digital strategy.
The Sandy, Utah facility has successfully operated for 70 years, employing over 1,000 people to produce critical medical components like peripheral intravenous catheters.
Becton, Dickinson and Company (BDX) reported a stock price of EUR 20.72 on the Lang & Schwarz exchange as of September 29, 2026. The article notes that no percentage change was stated for this specific dormant quote, serving primarily as a reference point for after-hours publication data.
Significant corporate developments occurred in late September 2026 regarding BDX's leadership and operations. Arthur Hu was named executive vice president and chief information and digital officer effective September 30, succeeding Denise Russell Fleming who is scheduled to retire at the end of 2026.
In a separate announcement on September 29, BDX celebrated a major manufacturing milestone at its Sandy, Utah facility, marking 70 years of operations. The company highlighted substantial investment and production capacity at this site as part of its global medical device manufacturing footprint.
π BDX stock listed at EUR 20.72 on September 29, 2026.
π€ Arthur Hu appointed CIO effective September 30, 2026.
Becton, Dickinson and Company (BDX) shares rose 2.56% to close at $183.82 on September 25, 2026, driven by a strong quarterly earnings beat. The medical technology firm reported Q3 fiscal 2026 revenue of $4.98 billion, surpassing the consensus estimate of $4.89 billion, while adjusted earnings per share reached $3.23 against a forecast of $3.14.
The company's financial performance highlighted robust growth with revenue increasing 5.4% year-over-year. Analysts maintain an average price target of $187.67, suggesting potential upside from current levels, though the consensus rating remains Hold with a balanced mix of Buy and Sell recommendations. The stock trades at a market capitalization of approximately $50.6 billion.
Looking ahead, BDX has provided fiscal 2026 adjusted EPS guidance ranging between $12.62 and $12.72, which aligns closely with the current analyst consensus of $12.67. The next earnings report is scheduled for November 5, 2026, providing investors with a clear checkpoint to monitor future performance trends in the medical instruments sector.
π BDX stock rose 2.56% to $183.82 after beating Q3 revenue and EPS estimates.
Becton Dickinson and Company reported fiscal third-quarter revenue of USD 5.0 billion, representing a 4.4 percent year-over-year increase. The medical technology firm posted adjusted earnings per share of USD 3.23 for the quarter ended June 30, 2026, while its stock price fell 1.28 percent to close at USD 180.19 on the NYSE.
Despite top-line growth, profitability faced headwinds as adjusted operating margins declined by 130 basis points to 24.9 percent in fiscal Q3 2026. The company attributed this margin pressure to tariffs and portfolio-related effects that are limiting the translation of revenue growth into operating profit.
Following the quarterly results, Becton Dickinson lifted its fiscal 2026 adjusted EPS guidance to a range of USD 12.62 to USD 12.72. Management also moved its full-year revenue outlook toward the high end of its previously stated low-single-digit growth range, signaling confidence in future performance despite current margin challenges.
The company currently holds a market capitalization of approximately USD 49.65 billion with shares trading below their 52-week high of USD 193.07. Investors are now focusing on execution and cost control as the primary measurable factors for the next earnings report.
π BDX Q3 revenue rose 4.4% to USD 5.0 billion.
π° Adjusted EPS reached USD 3.23 for the quarter.
π Operating margins dropped 130 bps to 24.9%.
π Fiscal 2026 EPS guidance lifted to USD 12.62-12.72.
π Full-year revenue outlook shifted toward high end of range.
π Becton Dickinson reported fiscal Q3 revenue of USD 5.0 billion, marking a 4.4 percent year-over-year increase.
π° Adjusted EPS reached USD 3.23 for the quarter ended June 30, 2026.
π Adjusted operating margins declined by 130 basis points to 24.9 percent due to tariffs and portfolio effects.
π The company lifted its fiscal 2026 adjusted EPS guidance to a range of USD 12.62 to USD 12.72.
π Revenue outlook was moved toward the high end of the low-single-digit growth range for the full year.
π Stock price fell 1.28 percent to USD 180.19 on September 24, 2026, trading below the 52-week high.
πΌ Market capitalization stands at USD 49.649 billion as of late September 2026.
π The company operates modern cleanroom manufacturing facilities for medical products globally.
Bullish Signals
Revenue rose 4.4% YoY to $5.0B in Q3 2026.
Adjusted EPS guidance lifted to $12.62-$12.72 for FY2026.
Full-year revenue outlook shifted toward high end of range.
Risk Factors
Operating margins declined 130 bps to 24.9% in Q3 2026.
Tariffs limit revenue growth translation into operating profit.
Stock fell 1.28% to $180.19, below 52-week high.
Bullish Signals
Becton Dickinson achieved a 4.4 percent year-over-year revenue increase to USD 5.0 billion in fiscal Q3 2026.
The company lifted its fiscal 2026 adjusted EPS guidance to a range of USD 12.62 to USD 12.72 following the quarterly report.
Management moved the full-year revenue outlook toward the high end of its low-single-digit growth range.
Risk Factors
Adjusted operating margins declined by 130 basis points to 24.9 percent in fiscal Q3 2026.
Tariffs and portfolio-related effects are currently limiting the translation of revenue growth into operating profit.
Stock price fell 1.28 percent to USD 180.19, trading below the 52-week high of USD 193.07.
Becton Dickinson and Company (BDX) closed its trading session on September 18, 2026, at USD 180.94 on the New York Stock Exchange. The stock experienced a modest decline of 0.24%, dropping by approximately USD 0.44 from the previous close of USD 181.38. Despite this slight downturn, the shares remained within their established intraday trading range, indicating a contained adjustment rather than a significant break in market structure or capitalization trends.
Market attention for BDX is currently focused on recent regulatory developments involving an SEC cease and desist settlement regarding past risk disclosures related to Alaris infusion pumps. This legal resolution includes the imposition of a civil penalty and the establishment of a Fair Fund intended to compensate affected investors. Market participants are actively assessing the potential implications of these terms on the company's reputation, future compliance costs, and its standing within the broader healthcare regulatory environment.
In addition to regulatory news, Becton Dickinson has a quarterly dividend scheduled for payment on September 30, 2026. This upcoming cash return is expected to influence sentiment among income-focused investors as the ex-dividend date approaches. The company's market capitalization was reported at approximately USD 52 billion during the session, reflecting its status as a major player in the medical device sector.
The stock's performance on September 18 contrasted with mixed broader market conditions, where the Dow Jones Industrial Average slipped while the Nasdaq Composite posted gains. BDX's decline slightly lagged the technology-heavy Nasdaq but aligned more closely with the softer performance of the Dow, suggesting that company-specific factors and regulatory headlines played a larger role in shaping its price action than general index direction.
π Stock closed at $180.94, down 0.24% from prior session.
βοΈ Facing SEC settlement over Alaris pump risk disclosures.
π° Quarterly dividend scheduled for September 30, 2026.
π Operates global cleanroom facilities with ~$52B market cap.
π Becton Dickinson stock closed at USD 180.94 on September 18, 2026, representing a 0.24% decline from the prior session of USD 181.38.
βοΈ The company is facing an SEC cease and desist settlement regarding past Alaris infusion pump risk disclosures, which includes a civil penalty and the creation of a Fair Fund for investors.
π° Becton Dickinson has a quarterly dividend scheduled to be paid on September 30, 2026, potentially boosting income-focused investor sentiment.
π The company operates modern cleanroom manufacturing facilities for medical products globally, maintaining a market capitalization of approximately USD 52 billion.
π BDX's modest loss was contained within its intraday range and contrasted with mixed broader market performance where the Nasdaq gained while the Dow slipped.
Bullish Signals
Market cap approx. USD 52 billion.
Dividend due Sept 30, 2026.
Risk Factors
Stock closed down 0.24% on September 18, 2026.
SEC settlement imposes penalty and creates Fair Fund.
Bullish Signals
The company maintains a substantial market capitalization of approximately USD 52 billion, indicating strong market presence.
A quarterly dividend is scheduled for payment on September 30, 2026, offering potential value to income-focused investors.
Risk Factors
The stock closed down 0.24% on September 18, 2026, reflecting a modest decline in share price.
An SEC cease and desist settlement regarding past Alaris infusion pump risk disclosures imposes a civil penalty and creates a Fair Fund for investors, potentially impacting reputation and compliance costs.
Becton Dickinson (BDX) is facing renewed regulatory and legal scrutiny stemming from two primary issues: a recent SEC cease-and-desist settlement regarding past risk disclosures for its Alaris infusion pump platform, and a plaintiff verdict against its subsidiary C.R. Bard in the PowerPort litigation. The company has agreed to pay a civil penalty and establish a Fair Fund for investors related to the Alaris matter.
Beyond these specific events, Becton Dickinson operates under a broader pattern of legal and compliance pressures that analysts are tracking closely. The combination of the SEC settlement findings and nearly 4,000 pending federal cases in the Bard PowerPort litigation introduces significant potential one-off items that could impact reported earnings and challenge the perception of consistently high-quality results.
Investors are advised to monitor how Becton Dickinson quantifies legal costs associated with the Alaris and Bard PowerPort issues in upcoming SEC filings, specifically looking for updated provisions or ranges of reasonably possible losses. These developments highlight heightened risks related to regulatory compliance, reimbursement complexities, and supply chain issues within the medical equipment industry.
The article notes that these legal and regulatory catalysts complicate the view of Becton Dickinson's financial position, particularly given its existing debt levels relative to operating cash flow. Analysts suggest that before relying on recent profit figures, investors should consider the underlying quality of earnings affected by these potential future liabilities.
βοΈ BDX settled SEC cease-and-desist over Alaris pump risk disclosures with civil penalty.
π Legal costs and debt concerns challenge view of BDX's high-quality earnings.
π Regulatory scrutiny on Alaris and Bard platforms central to BDX operations.
π Investors must watch filings for quantification of Alaris and Bard legal costs.
π Becton Dickinson reached an SEC cease-and-desist settlement regarding past risk disclosures for its Alaris infusion pump platform.
βοΈ The company agreed to a civil penalty and the creation of a Fair Fund for investors as part of the Alaris settlement.
β οΈ Subsidiary C.R. Bard recently faced a plaintiff verdict in PowerPort litigation with thousands of related product liability cases still pending.
π Nearly 4,000 federal cases remain pending in connection with the Bard PowerPort litigation, adding layers of potential financial impact.
π Analysts highlight that these legal pressures tie into a wider pattern of regulatory and compliance scrutiny for Becton Dickinson.
π° The SEC settlement findings regarding disclosure and controls sit uncomfortably next to concerns about Becton Dickinson's debt coverage by operating cash flow.
π Investors are urged to watch upcoming SEC filings for how Becton Dickinson quantifies Alaris and Bard PowerPort legal costs.
π₯ Regulatory and product safety scrutiny around platforms like Alaris and Bard PowerPort is central to Becton Dickinson's operations in the medical equipment industry.
π Potential one-off items from these litigations could affect reported earnings and challenge the view of consistently high-quality results.
Risk Factors
SEC penalty for Alaris disclosure failures.
Fair Fund required for investors.
Bard PowerPort verdict shows liability risks.
4,000 pending cases threaten earnings stability.
Compliance concerns and debt complicate view.
Risk Factors
Becton Dickinson reached an SEC cease-and-desist settlement over past Alaris infusion pump risk disclosures, resulting in a civil penalty.
The company is required to create a Fair Fund for investors as part of the resolution regarding the Alaris platform.
Subsidiary C.R. Bard recently faced a plaintiff verdict in PowerPort litigation, indicating ongoing product liability risks.
Thousands of related product liability cases remain pending against the Bard subsidiary, creating significant legal exposure.
Nearly 4,000 federal cases are still pending in connection with the Bard PowerPort litigation, posing a risk to earnings stability.
The SEC settlement findings regarding disclosure and controls raise concerns about internal compliance at Becton Dickinson.
Legal and regulatory pressures surrounding Alaris and Bard PowerPort highlight heightened risks in the medical equipment sector for Becton Dickinson.
These legal issues complicate the view of Becton Dickinson's financial position, particularly given its debt levels relative to operating cash flow.
Potential one-off items from these litigations could negatively affect reported earnings and challenge the perception of high-quality results.
Becton, Dickinson and Company (BDX) shares rose 2.1% to close at $181.59 on the NYSE on September 14, 2026, outperforming the broader S&P 500 which fell 0.5%. The stock's gain was driven by positive earnings guidance and a declared quarterly dividend of $1.05 per share, supporting its appeal to income-focused investors.
Financially, the company reported Q2 earnings of $3.23 per share, beating analyst consensus estimates of $3.14. For fiscal year 2026, BDX has provided guidance for EPS between $12.62 and $12.72, which aligns closely with the average analyst forecast of approximately $12.67. Analysts currently maintain a 'Hold' rating with an average price target of $187.67, implying potential upside from current levels.
Beyond earnings, BDX continues to invest in its medical technology portfolio, specifically deploying its Vmax 160 system for intelligent pharmacy automation. The company maintains a market capitalization of approximately $49 billion. However, the stock faces headwinds regarding dividend sustainability, as the reported payout ratio stands at roughly 126.5%, indicating the current distribution exceeds reported earnings.
Investors should also note ongoing legal proceedings involving the Becton Fair Fund, which is accepting claims from shareholders who purchased stock between February 2019 and February 2020. The fund is currently processing these claims with a bar date set for December 13, 2026, representing a specific risk factor within the company's broader risk profile.
π BDX stock rose 2.1% to $181.59, outperforming the S&P 500.
π° Quarterly dividend of $1.05 yields ~2.3%, though payout ratio is 126.5%.
π Q2 EPS beat estimates at $3.23, surpassing consensus by 2.87%.
π― FY 2026 EPS guidance of $12.62-$12.72 aligns with analyst forecasts.
β οΈ Legal fair fund accepts claims for shares held Feb 2019-2020.
π Becton Dickinson stock closed up 2.1% at $181.59 on September 14, 2026, outperforming the S&P 500 in a weak market session.
π° The company declared a quarterly dividend of $1.05 per share with an annualized yield of approximately 2.3%.
π Becton Dickinson beat Q2 earnings estimates with $3.23 EPS, surpassing the consensus of $3.14 by 2.87%.
π― Management provided FY 2026 guidance for EPS between $12.62 and $12.72, aligning with analyst forecasts.
π€ The company is deploying its Vmax 160 system to advance intelligent pharmacy automation in hospital environments.
βοΈ Analyst consensus rates the stock as a 'Hold' with an average price target of $187.67.
β οΈ The dividend payout ratio is approximately 126.5%, suggesting the distribution exceeds current reported earnings.
βοΈ A legal fair fund process is accepting claims from investors who held stock between February 2019 and February 2020.
Payout ratio of 126.5% suggests unsustainable dividends.
Legal fund accepts claims for Feb 2019-2020 buyers.
Bullish Signals
Becton Dickinson shares gained 2.1% to close at $181.59, outperforming the S&P 500 which declined 0.5% in the same session.
The company delivered a positive earnings surprise of 2.87% in the most recent quarter with EPS of $3.23 versus an estimate of $3.14.
Becton Dickinson provided FY 2026 guidance for EPS between $12.62 and $12.72, which aligns closely with the average analyst forecast of $12.67.
The company declared a quarterly dividend of $1.05 per share, providing an annualized yield of approximately 2.3% to income-focused investors.
Risk Factors
The reported payout ratio is approximately 126.5%, indicating that the current dividend exceeds reported earnings and raising questions about sustainability.
An ongoing legal fair fund process is accepting claims from shareholders who purchased stock between February 2019 and February 2020, representing a specific risk factor.
Becton, Dickinson and Company (BDX) closed lower on the New York Stock Exchange on September 11, 2026, recording a modest loss as share prices eased in a relatively calm trading session. The daily decline reflected a minor negative move against the prior close, with intraday activity remaining within a narrow band between the day's low and high.
Trading volume for BDX was moderate, indicating subdued investor activity relative to busier sessions earlier in the month. The stock remained within its established 52-week range according to major US quote data providers, suggesting stability despite the short-term dip.
Institutional ownership data indicates that The Manufacturers Life Insurance Company recently reduced its stake in Becton, Dickinson and Company, signaling some portfolio repositioning around the security. Analyst consensus currently rates the stock as a 'hold' with an average target price positioned modestly above the latest closing level.
Looking ahead to the market open, BDX faces no major company-specific catalysts such as earnings releases or annual meetings within the immediate five-trading-day window. Consequently, the stock's performance will likely be influenced by broader US economic releases and general healthcare-sector news rather than specific corporate developments.
π BDX finished lower on Sept 11, 2026 with modest loss.
π¦ Manufacturers Life Insurance reduced stake in BDX portfolio.
π― Analyst consensus holds BDX with target price above close.
π Future performance driven by US economy and healthcare news.
π Becton, Dickinson and Company (BDX) finished lower on September 11, 2026, posting a modest loss in a quiet trading session on the NYSE.
π Intraday share turnover for BDX reached a moderate level, reflecting subdued activity compared to busier days earlier in the month.
π¦ Institutional investor The Manufacturers Life Insurance Company recently reduced its stake in Becton, Dickinson and Company, indicating portfolio repositioning.
π― Analyst consensus maintains a 'hold' rating for BDX with an average target price modestly above the latest closing price.
π Becton, Dickinson and Company has no major company-specific events scheduled within the immediate five-trading-day window ahead of the next session.
π The stock's future performance is expected to be driven by broader US economic releases and general healthcare-sector news rather than specific corporate catalysts.
Risk Factors
Manufacturers Life Insurance reduced its stake.
Stock closed lower with a modest loss.
Risk Factors
Institutional investor The Manufacturers Life Insurance Company recently reduced its stake in Becton, Dickinson and Company, indicating some portfolio repositioning away from the stock.
Becton, Dickinson and Company closed lower on September 11, 2026, recording a modest loss as share prices eased in a relatively calm trading session.
Becton, Dickinson and Company (BDX) shares edged lower on September 8, 2026, trading at $179.10 after management highlighted a strategic shift toward a slimmer portfolio following the spin-off of Embecta and the separation of its life sciences business to Waters. At the Wells Fargo Healthcare Conference, executives emphasized that fiscal third quarter 2026 marked the first full period of operation as a more focused entity, delivering 4.4% organic revenue growth with roughly 90% of the portfolio achieving high-single-digit expansion.
Looking ahead, the company raised its full-year guidance for fiscal 2026 to the upper end of the low-single-digit range, signaling confidence that recent momentum can be sustained. However, management issued a cautious outlook for fiscal 2027, projecting only low-single-digit revenue growth due to mechanical headwinds from the Alaris infusion system comparison and pricing pressures in China. The company quantified these specific headwinds at approximately 250 basis points for fiscal 2026 and roughly 200 basis points for fiscal 2027.
Capital allocation remains a key pillar of BD's strategy, with management noting that around $2 billion in proceeds from the Waters transaction have been utilized for share repurchases in fiscal 2026. Additionally, the company declared a quarterly dividend of $1.05 per share with an ex-dividend date of September 9, 2026, offering a yield of approximately 2.3% at current prices. Analyst consensus currently rates BDX as a Hold with an average target price of $187.67, suggesting the stock trades slightly below fair value estimates.
π Shares closed down 3.0% at $179.10 on September 8, 2026.
π Full-year 2026 guidance raised to upper low-single-digit range.
β οΈ Fiscal 2027 outlook cautious with ~200 bps mechanical headwind.
π° Used $2 billion Waters proceeds for share repurchases in 2026.
π Becton, Dickinson and Company shares closed down 3.0% at $179.10 on September 8, 2026, trading within its 52-week range of $127.62 to $193.07.
π The company reported 4.4% organic revenue growth in fiscal Q3 2026, marking the first full quarter operating as a focused entity post-divestitures.
π Management raised full-year guidance for fiscal 2026 to the upper end of the low-single-digit range, projecting sustained momentum from recent performance.
β οΈ Fiscal 2027 outlook is cautious with low-single-digit growth expectations due to a mechanical headwind of roughly 200 basis points from Alaris infusion system comparisons.
π Pricing pressures in China contributed approximately 250 basis points of headwinds to fiscal 2026 revenue, offset by positive pricing elsewhere in the global portfolio.
π° The company utilized around $2 billion from the Waters transaction proceeds for share repurchases in fiscal 2026 to return capital to shareholders.
π΅ BDX declared a quarterly dividend of $1.05 per share with an ex-dividend date of September 9, 2026, annualizing to a yield of about 2.3%.
π― Analyst consensus maintains a Hold rating with an average target price of $187.67, placing the current stock price roughly 4.8% below the mean target.
π GuruFocus data indicates BDX shares trade approximately 2.6% below its proprietary GF Value estimate of $183.88 as of September 8, 2026.
Bullish Signals
Organic revenue grew 4.4% in Q3 2026.
Raised full-year guidance to upper low-single digits.
Absorbed $130M China price impact with positive pricing.
Used $2B Waters proceeds for share repurchases.
Declared $1.05 quarterly dividend yielding 2.3%.
Risk Factors
Alaris, vaccines, and China pricing caused ~250 bps headwinds to FY26 revenue growth.
China value-based procurement programs negatively impacted reported revenue.
Bullish Signals
Becton, Dickinson and Company achieved 4.4% organic revenue growth in fiscal Q3 2026, demonstrating strong momentum across roughly 90% of its portfolio following strategic divestitures.
Management raised full-year guidance for fiscal 2026 to the upper end of the low-single-digit range, signaling confidence that recent performance can be sustained throughout the year.
The company successfully absorbed over $130 million in negative price impact from China's value-based procurement programs while maintaining positive pricing across the rest of its fiscal 2026 operations.
BD utilized approximately $2 billion in proceeds from the Waters transaction for share repurchases in fiscal 2026, reinforcing its commitment to capital returns alongside growth investments.
The company declared a quarterly dividend of $1.05 per share with an ex-dividend date of September 9, 2026, providing income-focused investors with a yield of about 2.3%.
Risk Factors
Combined pressures from the Alaris system, vaccines, and China pricing created approximately 250 basis points of headwinds to fiscal 2026 revenue growth.
The company faces ongoing pricing pressure in China due to value-based procurement programs, which negatively impacted reported revenue despite offsetting gains elsewhere.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)